On Wednesday, Shares of Ultra Clean Holdings Inc (NASDAQ:UCTT), added 6.01% and closed at $9.70 in the last trading session. The last trading range of the stock ranges between $9.20 and $9.72. Ultra Clean Holdings, Inc. designs, develops, prototypes, engineers, manufactures, and tests production tools, modules, and subsystems for the semiconductor capital equipment and equipment industry segments mainly in North America, Asia, and Europe. It offers precision robotic systems that are used when accurate controlled motion is required; robotic surgery products; gas delivery systems, which include one or more gas lines consisting of small diameter internally polished stainless steel tubing products, filters, mass flow controllers, regulators, pressure transducers and valves, component heaters, and an integrated electronic and/or pneumatic control system; and various industrial and automation production equipment products. The company also provides subsystems, such as wafer cleaning sub-systems; chemical delivery modules that deliver gases and reactive chemicals in a liquid or gaseous form from a centralized subsystem to the reaction chamber; frame assemblies, which are support structures fabricated from steel tubing or folded sheet metal; and top-plate assemblies.
SAGE Therapeutics Inc (NASDAQ:SAGE), dropped -6.36% and closed at $52.00 in the last trading session. The last trading range of the stock ranges between $51.80 and $55.17. The company’s Market capitalization is $1.97 Billion with the total Outstanding Shares of 37.17 million. Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, recently declared that the European Medicines Agency (EMA) has granted its PRIority MEdicines (PRIME) designation to SAGE-547 for the treatment of postpartum depression (PPD). The SAGE-547 application for the PRIME designation was based on the positive clinical results from the placebo-controlled 202A study of SAGE-547 in severe PPD. In September, the U.S. Food and Drug Administration (FDA) granted SAGE-547 Breakthrough Therapy Designation for the treatment of PPD.
The PRIME program was launched by the EMA in March 2016, and the designation is designed to aid and expedite the regulatory process for investigational medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. To be accepted, an investigational medicine must show the potential to benefit patients with unmet medical needs based on early clinical data.
“This priority medication designation for SAGE-547 within the EMA’s new PRIME program reflects the urgent need for treatment options for women suffering with postpartum depression and was supported by the promising clinical data from our Phase 2 study,” said Jeff Jonas, M.D., Chief Executive Officer of Sage. “We look forward to working with the EMA to determine the appropriate regulatory path to support a European marketing authorization application for SAGE-547 in PPD as we initiate planning for our European operations and clinical trial infrastructure.”